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Abstract 
Objective: The progestin dienogest (DNG) given alone effectively reduces pelvic pain of women 
with endometriosis. It is not clear whether the same occurs when DNG is associated with estradiol 
(E2).  
Design: Patient preference prospective observational study. 
Setting: Outpatient centre of university hospital. 
Patients: 40 patients with endometriosis and menstrual pain. 
Interventions: 24-week treatment with a quadriphasic association of estradiol valerate (E2V) and 
DNG or a non-steroidal anti-inflammatory drug (NSAID) to be used only in case of pain 
(ketoprofene 200 mg tablets).  
Main Outcome Measures: Menstrual pain and, when present, inter-menstrual pain and 
dyspareunia were investigated by means of a 10 cm visual analogic scale (VAS). Quality of life was 
investigated by the short form-36 of the health related quality of life (SF-36) questionnaire.  
Results: Final study group consists of 34 patients, 19 in the E2V/DNG group and 15 in the NSAID-
group. After 24 weeks no significant modification of menstrual pain, inter-menstrual pain, 
dyspareunia or SF 36-score was observed in the NSAID-group. Treatment with E2V/DNG reduced 
the VAS score of menstrual pain by 61% (p<0.0001). In the subgroups of women with inter-
menstrual pain or dyspareunia, E2V/DNG reduced these complaints by 65% (p=0.013) and 52% 
(p=0.016), respectively. The reduction of menstrual (p=0.0001) and inter-menstrual pain (p=0.03) 
was significantly greater during E2V/DNG than NSAID. Quality of life improved during E2V/DNG 
(p=0.0002), both in physical (p=0.0003) and mental domains (p=0.0065). Only few minor adverse 
effects were described during E2V/DNG, and none caused withdrawal from treatment.  
Conclusion: In patients with endometriosis and pelvic pain, the 24-week administration of the 
quadriphasic association of E2V/DNG decreases pelvic pain and improves quality of life. 
Keywords (n=11): Endometriosis, Dysmenorrhea, Chronic Pelvic Pain, Dyspareunia, Quality Of 
Life, Hormonal Contraception, Combined Oral Contraceptive, Dienogest, Estradiol Valerate, 
NSAID, Ketoprofene 
 
 
Introduction 
Endometriosis is a chronic disease that affects about 10% of women in reproductive age. It is 
associated with recurrent episodes of menstrual or inter-menstrual pain and deep dyspareunia[1, 2]. 
These may have a negative impact on the woman’s quality of life [3]. Combined oral contraceptives 
(COCs) are an accepted and effective medical therapy for menstrual pain related to endometriosis 
[4-7]. Among different types of progestins used in COCs, a particular role belongs to dienogest 
(DNG). In women with endometriosis, DNG given alone at a dose of 2 mg/day reduces pain [8], in 
a way similar to that obtained with a GnRH analogue [9,10]. The effect over-lasts its use [11] and is 
associated with improved quality of life [9,12]. Direct effects of DNG on growth, neo-angiogenesis 
and cell proliferation of endometriotic lesions have been also reported [13-15]. In addition to the 
cost, two aspects may limit the widespread and prolonged use of DNG alone. DNG alone is not 
licensed as a method for contraception, and sexually active women should use additional non-
hormonal contraceptive method. Furthermore, the use of DNG alone is associated with a high 
incidence of irregular uterine bleedings, with values ranging from 13.3% [11] to 71.9% [16]. This 
may lead to a low acceptance and an early discontinuation of DNG treatment [9-11]. Both 
contraception and cycle control can be achieved with the addition of an estrogenic component to 
DNG. Indeed, DNG is marketed in two COC formulations, one containing estradiol valerate (E2V) 
and the other ethinyl-estradiol (EE). At the moment, it is not clear whether the efficacy of DNG in 
the treatment of pain associated with endometriosis could be eliminated by the addition of an 
estrogenic component. 
In this study we evaluated the efficacy of DNG associated with E2V in reducing pelvic pain and in 
improving quality of life of women with endometriosis. 
The present study is reported according to the STROBE statement for improving the quality of 
observational studies (http://www.strobe-statement.org). 
Material and methods 
A patient preference, observational, prospective cohort mono-centric study, was performed at the 
University Hospital of Modena (Italy) in the outpatient service for endometriosis and chronic pelvic 
pain. The study was performed between January 2011 and June 2013, and it was conducted in full 
accordance with the World Medical Association Declaration of Helsinki. The institutional review 
board (IRB) of our institution approved this observetional study. Each patient was enrolled into the 
study after having signed a specific informed consent for the use of her sensitive data. Exclusion 
criteria were: women with contraindications to the use of COC (category 3 and 4 of WHO 
guidelines) [17], women having undergone surgical treatment or having used hormonal 
contraceptives, progestins, GnRHa or other treatments for pain or endometriosis in the previous 3 
months. 
Inclusion criteria were: subjects of normal weight (BMI < 25), 18 to 50 years of age, with regular 
menstrual cycles, suffering from menstrual pain from more than 6 months. All women suffered 
from symptomatic endometriosis (diagnosed by previous laparoscopy or laparotomy or the presence 
of an ovarian endometrioma diagnosed by trans-vaginal ultrasound) and were not scheduled for first 
or repeated surgery. Women were informed about the different pharmacologic options available for 
the treatment of their pain. Those women who spontaneously chose either the COC under 
investigation or a non-steroidal anti-inflammatory drug (NSAID) were enrolled into the study [18]. 
The COC under investigation was a quadriphasic oral contraceptive containing E2V/DNG (days 1-
2: 3mg E2V, days3-7: 2 mg E2V+2 mg DNG, days 8-24: 2 mg E2V+3 mg DNG, days 25-26: 1 mg 
E2V, days 27-28: placebo) (Klaira®, Bayer Schering Pharma, Milan, Italy). The NSAID was 
ketoprofene 200 mg tablets (Orudis®, Sanofi Aventis SpA, Milan, Italy) to be taken only when 
needed, not exceeding three times a day. Both treatments were prescribed for 24 weeks. At the time 
of study start-up, DNG alone was not available in Italy, and E2V/DNG was the only COC 
containing DNG available in our country. Women interested to participate were enrolled after 
having signed an informed consent. Subjects paid for their medicines as in real life condition. 
Patients were evaluated prior to treatment, on days 2-5 of menstrual phase and on days 2-5 of the 4th 
and 7th cycle of treatment. Side effects, tolerability, pain and quality of life were evaluated prior to 
and at the end of the six cycles, while adverse events and tolerability were evaluated also at the end 
of the first 12 weeks of treatment.  
Height and weight were measured barefoot with the subject wearing light clothes. BMI (Kg/m2) 
was calculated. A 10-cm visual analogue scale (VAS) was used to measure intensity of menstrual 
pain, inter-menstrual pain and dyspareunia [19]. A validated Italian version of the SF-36 
questionnaire [20] was used to quantify health-related quality of life.    
 
Data analysis 
Statistical analysis was performed using the statistical package StatView (version 5.01.98, SAS 
Institute Inc, Cary, NC, USA). Intra-group analysis was performed with the t-test for paired data 
and by the Wilcoxon signed-rank test for normal and non-normal data distribution, respectively. 
Between groups comparison was performed by two factors analysis of variance (ANOVA) for 
repeated measures, with treatment and time as factor 1 and factor 2 and subjects as replicates.  
For all analyses the null hypothesis was rejected at a two-tailed p value <0.05. Results are expressed 
as the mean ± standard deviation (SD). 
 
Potency of the study 
Sample dimension was calculated on possible modification of menstrual pain VAS score. Based on 
a previous study performed with an EE based COC [7], during E2V/DNG we assumed a VAS score 
decrease of about 3.1 with a SD of about 2.0. Similarly, we assumed a non-significant effect of 
NSAID with a maximum VAS score decline of 1 and a SD of 2.0. The number of participants 
required to detect a significant difference at a p-value of 0.05 was 14 participants for each arm. 
Assuming a patient withdrawal of about 20% we set our sample size to 18 subjects for group. 
The final group of enrolled women was 22 subjects in the E2V/DNG group and 18 subjects in the 
NSAID-only group.  
Results 
A total of 40 women were included into the study, 22 in the E2V/DNG group and 18 in the NSAID-
only group. One woman discontinued E2V/DNG during the second cycle of treatment for desire of 
pregnancy. Two women in the E2V/DNG group and 3 in the control group did not want to repeat 
scheduled controls. Accordingly, analyses were performed in the 34 women who finished the study 
(19 in the E2V/DNG group and 15 in the NSAID-only group). Treatment continuation was similar 
in the E2V/DNG and the NSAID-only group (86.4% vs. 83.3%). Features of patients analyzed in 
the two groups did not differ at baseline (Table 1). 
 
E2V/DNG group 
Pelvic pain and quality of life 
Among enrolled women, all suffering from menstrual pain, 11 (57.9%) also suffered from inter-
menstrual pelvic pain and 13 (68.4%) from deep dyspareunia.  
During the 24-week treatment mean VAS score of menstrual pain decreased by 61% (p=0.0001). 
Furthermore, in the subgroups of women with inter-menstrual pain and dyspareunia, these 
complaints decreased by 65% (p=0.013) and 52% (p=0.016), respectively (Figure 1 Table 2). 
In a post-hoc analysis, we considered how many subjects exceeded a VAS score of 4 for each type 
of pain. For menstrual pain, the number was14 at baseline and 4 after 6 cycles of treatment (73.7% 
vs. 21.0%; p<0.001). In these women the mean VAS score declined from 7.99±1.68 to 3.02±2.19 (-
59.9%±29.95; p<0.0001). For inter-menstrual pain, the number was 7 at baseline and 1 after 6 
cycles of treatment  (63.6% vs. 9.1%; p<0.01). In these women the mean VAS score declined from 
7.57±2.03 to 1.87±3.06 (-80.2%±28.8%; p=0.008). For deep dyspareunia, the number was 9 at 
baseline and 3 at the end of treatment  (69.2% vs. 23.1%; p=0.018). In these women the mean VAS 
score declined from 7.30±1.95 to 2.66±2.92 (-65.7%±36.5%; p=0.001). 
During treatment we observed a significant increase in total SF-36 score (from 58.41±21.75 to 
69.82±16.88; p=0.0002) and in its physical (from 55.85±24.05 to 70.53±18.80; p=0.0004) and 
mental (from 57.17±26.31 to 67.72±19.47; p=0.007) general domains (Figure 2 Table 3). In 
particular, a significant increase in bodily pain (from 43.68±28.63 to  67.89±23.53; p=0.0004), 
physical functioning (from 67.63±30.34 to  80.53±23.39; p=0.007) and role-physical (from 
61.84±43.60 to 77.63±32.16; p=0.048) was observed for the physical domains, and in vitality 
(from 48.42±24.21 to 56.84±19.45; p=0.022) and social functioning (from 49.87±34.44to 
70.39±28.21; p=0.007) for the mental domains (Figure 2 Table 3).     
 
Adverse effects 
During the first cycle of therapy spotting was experienced by 2/19 (10.5%) of patients. It was 
spontaneously resolved within the second cycle of treatment. No major adverse effects were 
reported. Regarding the minor effects, headache was reported by 4/19 (21.1%), bloating by 2/19 
(10.5%), irritability and fatigue by 1/19 (5.2%) of cases. None of these symptoms lead to treatment 
withdrawal. 
 
NSAID-only group 
Pelvic pain and quality of life 
All enrolled women were suffering from menstrual pain, and among these 12 (80%) also suffered 
from inter-menstrual pain and 8 (53.3%) from deep dyspareunia. 
In this group of patients we did not observe any modifications of any pelvic pain score (Figure 1 
Table 2).   
Similarly the SF-36 score and its domains did not vary, with the exception of an isolated 
improvement in the vitality score (from 42.08±14.99 to 56.94±22.76; p=0.014) (Figure 2 Table 3). 
 
Adverse effect 
No particular adverse effect was reported by women of this group. 
Discussion 
Main results 
Effect on pelvic pain 
This 24-week preliminary pilot study shows that a COC containing DNG associated in a 
quadriphasic fashion to E2V significantly reduces pelvic pain and improves quality of life of 
women with endometriosis. By contrast, and in accordance with a recent meta-analysis [21], 
NSAIDs are ineffective in reducing pain and improving quality of life. 
The effect of E2V/DNG is not exerted only on menstrual pain but also on inter-menstrual pain and 
deep dyspareunia. These effects are rather impressive, particularly in women with intense pain, 
where E2V/DNG is capable of reducing by about 60% menstrual pain, by 80% inter-menstrual pain 
and by 65% deep dyspareunia. These improvements are associated with an amelioration of quality 
of life. Obviously, menstrual pain can be improved by avoiding menstrual bleeding. Accordingly, 
continuous regimens of combined hormonal contraceptives are capable to markedly affect 
menstrual pain [22,23] with a maximal reduction up to 87.5%, which was obtained with the non-
contraceptive association of EE 10 mcg and cyproterone acetate 3 mg [24]. The effect on menstrual 
pain is less evident when combined hormonal contraceptives are administered in a cyclic fashion, 
with studies reporting either no effect [25], or a decrease of menstrual pain not superior to 55% 
[7,23,26-28]. In our study, E2V/DNG given cyclically induced a decline of the menstrual pain VAS 
score of about 60%, which is similar to the one observed with other combined hormonal 
contraceptives cyclically administered. What is interesting with the E2V/DNG administration, it is 
the amelioration of inter-menstrual pain. Inter-menstrual pain decreased by about 60%, but in very 
symptomatic women the score declined by about 80%. In the literature, several studies did not 
evaluate the effect of hormone administration on inter-menstrual pelvic pain [22,29,30]. Among 
those that performed this evaluation, inter-menstrual pain was either not improved [23,25,28] or 
only slightly improved. Improvements did not exceed a 30% VAS score reduction [7,24,26,27]. 
Only in one study inter-menstrual pain decreased by 52%, but this result was obtained with the 
administration of a non-contraceptive association containing 10 mcg EE and 3 mg cyproterone 
acetate [23]. Deep dyspareunia was also not investigated in some studies [7,29,30], in others it was 
unaffected [23,25], and in others again it was improved by therapy [22,26-28]. The reductions of 
the VAS score for dyspareunia was reported in the range of about 35%, with the exception of one 
study, where the non-contraceptive association of EE (10 mcg) and cyproterone acetate (3 mg) 
decreased it by 78.3% [24]. In our study the decline of the VAS score for dyspaurenia was 52% 
reaching about 70% in very symptomatic women.  
Accordingly, present data indicate that E2V/DNG is highly effective in reducing all types of pelvic 
pain of women with endometriosis. In agreement with our results, a retrospective study reported a 
high efficacy of quadriphasic E2V/DNG in the treatment of pelvic pain of patients who had 
undergone surgery for endometriosis [31]. 
The possible explanation for this “triple” action on menstrual, inter-menstrual pain and dyspareunia 
may depend on several factors. 
In comparison to the traditional 7 days hormone-free interval the reduction of the hormone-free 
interval, with an almost continuous regimen (2 days of hormone-free interval), is associated with a 
decrease of hormone-withdrawal-associated symptoms [32-34]. 
DNG has a strong endometrial affinity and it may directly decrease growth, neoangiogenesis and 
proliferation of endometriotic lesions [7-14]. In our study DNG was used at doses sufficient to 
perform this clinical effect. The cumulative exposure per cycle to DNG was about 2.2 mg/day, 
which is comparable to that approved for the treatment of endometriosis (2 mg/day) [8-12]. 
It is likely that the circulating levels of E2 induced by E2V/DNG, with values ranging between 60-
90 pg/ml [32], were not capable to counteract the potent effect of DNG on endometriotic lesions. 
Large randomized clinical comparative trials on this topic are mandatory.  
On the other hand, the presence of the step-down estrogen component (E2V) could represent an 
advantage in terms of bleeding control and therapy adherence [32-35]. In the present study 10.5% 
of patients experienced irregular bleedings, which were confined  to the first cycle of treatment, and 
less frequent than those reported for DNG alone [8-12,16]. 
 
Effect on quality of life 
Pelvic pain, in particular inter-menstrual pain and, in lesser extent, menstrual pain, is associated 
with a reduced quality of life [19]. Accordingly, improvements in pelvic pain in women with 
endometriosis are expected to improve quality of life, as herein shown. A comparable (≈10 points 
SF- 36) increase in quality of life was already observed with the administration of DNG alone in 
women with endometriosis [9,12]. To our knowledge there is no previous prospective evidence that 
any hormonal combined contraceptive can increase, per se, quality of life of women with 
endometriosis [25]. 
 
Limitations 
The non-random allocation to treatments constitutes a drawback of the present study. About this we 
shared the approach proposed by Vercellini et al. [22], using a research environment more similar to 
the “real world” conditions. Even the small sample size undoubtedly limits the strength of our 
results. However, in view of the lack of prospective data on the use of E2V/DNG for endometriosis-
related pain, we decided first to conduct a small pilot study. 
 
In conclusion, in patients with endometriosis it is still unknown if the administration of estrogens 
should be completely avoided or could be permitted in low dosages. Waiting for large randomized 
trials, in this study we demonstrated that the 24-week administration of quadriphasic E2V/DNG 
combination is associated with a reduction of pelvic pain and an improvement of quality of life of 
patients with symptomatic endometriosis. 
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Legend for Figures 
Figure 1 
Mean (+SD) visual-analogic scale (VAS) score of menstrual pain, inter-menstrual pain and deep 
dyspareunia evaluated prior to and after 6 cycles of treatment with E2V/DNG or NSAID-only. 
** p < 0.025 vs. Basal; *** p < 0.01 vs. Basal; § p < 0.05 vs. NSAID-only group; §§§ p < 0.01 vs. 
NSAID-only group 
 
Figure 2 
Mean (+SD) SF-36 scores and its domains sub-scores (physical and mental) evaluated prior to and 
after 6 cycles of treatment with E2V/DNG or NSAID-only. 
* p < 0.05 vs. Basal; ** p < 0.025 vs. Basal; *** p < 0.01 vs. Basal 
  
 
 
 
 
 
 
 
